Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Esperanza B. Papadopoulos

Early Fluid Overload Is a Serious Toxicity Associated With an Increased Risk of Non-Relapse Mortality After Ex-Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

Ex Vivo CD34+–Selected T Cell–Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated With Low Incidence of Acute and Chronic Graft-Versus-Host Disease and High Treatment Response

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2017

English

Empiric Anti-Thymocyte Globulin (ATG) Dosing in Ex-Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-Hct) May Result in ATG Overexposure That Negatively Affects Outcomes

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

Double-Unit Cord Blood (CB) Transplantation (dCBT) Supplemented With Haplo-Identical CD34+ Cells May Be Associated With Enhanced Neutrophil Recovery but Successful Myeloid Bridging Is Strongly Influenced by Haplo CD34+ Cell Dose and Haplo-Winning CB Unit HLA-Match

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2019

English

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes Between CD34 + Selected or Unmodified Hematopoietic Stem Cells Transplants

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

Impact of Pre-Transplant Measurable Residual Disease on Relapse Incidence and Progression-Free Survival in Older AML/MDS Patients Following Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2019

English

Ex Vivo T Cell–Depleted Versus Unmodified Allografts in Patients With Acute Myeloid Leukemia in First Complete Remission

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2013

English

Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients With Hepatosplenic T-Cell Lymphoma: A Single Institution Experience.

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Esperanza B. Papadopoulos

Early Fluid Overload Is a Serious Toxicity Associated With an Increased Risk of Non-Relapse Mortality After Ex-Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

Ex Vivo CD34+–Selected T Cell–Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated With Low Incidence of Acute and Chronic Graft-Versus-Host Disease and High Treatment Response

Empiric Anti-Thymocyte Globulin (ATG) Dosing in Ex-Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-Hct) May Result in ATG Overexposure That Negatively Affects Outcomes

Double-Unit Cord Blood (CB) Transplantation (dCBT) Supplemented With Haplo-Identical CD34+ Cells May Be Associated With Enhanced Neutrophil Recovery but Successful Myeloid Bridging Is Strongly Influenced by Haplo CD34+ Cell Dose and Haplo-Winning CB Unit HLA-Match

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes Between CD34 + Selected or Unmodified Hematopoietic Stem Cells Transplants

Impact of Pre-Transplant Measurable Residual Disease on Relapse Incidence and Progression-Free Survival in Older AML/MDS Patients Following Allogeneic Hematopoietic Cell Transplantation

Ex Vivo T Cell–Depleted Versus Unmodified Allografts in Patients With Acute Myeloid Leukemia in First Complete Remission

Intensive Induction Chemotherapy Followed by Early High-Dose Therapy and Hematopoietic Stem Cell Transplantation Results in Improved Outcome for Patients With Hepatosplenic T-Cell Lymphoma: A Single Institution Experience.